For the quarter ending 2025-12-31, SNOA had -$474K decrease in cash & cash equivalents over the period. -$811K in free cash flow.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | -819 | -534 | -1,241 |
| Depreciation | 34 | 36 | 36 |
| Stock-based compensation | 24 | 39 | 57 |
| Deferred tax asset | - | -141 | - |
| Deferred income taxes | -107 | - | -93 |
| Operating lease right-of-use asset | 161 | -56 | 448 |
| Accounts receivable, net | -340 | 78 | 216 |
| Inventories, net | 40 | -208 | 652 |
| Prepaid expenses and other current assets | 392 | 15 | 819 |
| Deferred consideration, net of discount | 62 | 59 | 55 |
| Accounts payable | 229 | -666 | 1,026 |
| Accrued expenses and other current liabilities | 78 | 158 | -484 |
| Withholding tax payable | 109 | 110 | 104 |
| Operating lease liabilities | 162 | -56 | 448 |
| Deferred revenue | -449 | 0 | 26 |
| Net cash (used in) provided by operating activities | -764 | -635 | -2,015 |
| Purchases of property and equipment | 47 | 10 | 106 |
| Net cash used in investing activities | -47 | -10 | -106 |
| Proceeds from issuance of common stock, net of offering expenses | 266 | 0 | 0 |
| Proceeds from exercise of employee stock options | 0 | 21 | 23 |
| Payments for fractional shares related to reverse-split | 0 | 0 | - |
| Principal payments on short-term debt | 56 | 83 | 81 |
| Net cash provided by financing activities | 210 | -62 | -58 |
| Effect of exchange rate on cash and cash equivalents | 127 | 137 | 410 |
| Net (decrease) increase in cash and cash equivalents | -474 | -570 | -1,769 |
| Cash and cash equivalents at beginning of period | 3,035 | 5,374 | - |
| Cash and cash equivalents at end of period | 2,561 | 3,035 | - |
Sonoma Pharmaceuticals, Inc. (SNOA)
Sonoma Pharmaceuticals, Inc. (SNOA)